Annual EBITDA
-$137.09 M
-$28.45 M-26.19%
31 December 2023
Summary:
Monte Rosa Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$137.09 million, with the most recent change of -$28.45 million (-26.19%) on 31 December 2023. During the last 3 years, it has fallen by -$109.62 million (-399.00%). GLUE annual EBITDA is now -1688.04% below its all-time high of -$7.67 million, reached on 31 December 2019.GLUE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$24.42 M
+$6.16 M+20.14%
30 September 2024
Summary:
Monte Rosa Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$24.42 million, with the most recent change of +$6.16 million (+20.14%) on 30 September 2024. Over the past year, it has increased by +$10.71 million (+30.48%). GLUE quarterly EBITDA is now -477.67% below its all-time high of -$4.23 million, reached on 31 March 2020.GLUE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$121.07 M
+$10.71 M+8.13%
30 September 2024
Summary:
Monte Rosa Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$121.07 million, with the most recent change of +$10.71 million (+8.13%) on 30 September 2024. Over the past year, it has increased by +$14.42 million (+10.64%). GLUE TTM EBITDA is now -2763.60% below its all-time high of -$4.23 million, reached on 31 March 2020.GLUE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GLUE EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -26.2% | +30.5% | +10.6% |
| 3 y3 years | -399.0% | -26.6% | -102.2% |
| 5 y5 years | - | - | - |
GLUE EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -399.0% | at low | -26.6% | +31.8% | -102.2% | +11.7% |
| 5 y | 5 years | -1688.0% | at low | -477.7% | +31.8% | -2763.6% | +11.7% |
| alltime | all time | -1688.0% | at low | -477.7% | +31.8% | -2763.6% | +11.7% |
Monte Rosa Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$24.42 M(-20.1%) | -$121.07 M(-8.1%) |
| June 2024 | - | -$30.58 M(-7.5%) | -$131.78 M(-3.8%) |
| Mar 2024 | - | -$33.05 M(+0.1%) | -$137.03 M(-0.0%) |
| Dec 2023 | -$137.09 M(+26.2%) | -$33.02 M(-6.0%) | -$137.09 M(+1.2%) |
| Sept 2023 | - | -$35.13 M(-1.9%) | -$135.49 M(+6.1%) |
| June 2023 | - | -$35.83 M(+8.2%) | -$127.69 M(+8.0%) |
| Mar 2023 | - | -$33.11 M(+5.4%) | -$118.20 M(+8.8%) |
| Dec 2022 | -$108.64 M | -$31.42 M(+15.0%) | -$108.64 M(+8.9%) |
| Sept 2022 | - | -$27.33 M(+3.7%) | -$99.80 M(+8.8%) |
| June 2022 | - | -$26.34 M(+11.9%) | -$91.75 M(+10.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$23.55 M(+4.3%) | -$83.07 M(+17.4%) |
| Dec 2021 | -$70.75 M(+157.5%) | -$22.58 M(+17.1%) | -$70.75 M(+18.1%) |
| Sept 2021 | - | -$19.29 M(+9.2%) | -$59.88 M(+27.9%) |
| June 2021 | - | -$17.66 M(+57.2%) | -$46.81 M(+35.8%) |
| Mar 2021 | - | -$11.23 M(-4.1%) | -$34.48 M(+25.5%) |
| Dec 2020 | -$27.47 M(+258.3%) | -$11.71 M(+88.5%) | -$27.48 M(+74.3%) |
| Sept 2020 | - | -$6.21 M(+16.7%) | -$15.77 M(+65.1%) |
| June 2020 | - | -$5.32 M(+25.9%) | -$9.55 M(+125.9%) |
| Mar 2020 | - | -$4.23 M | -$4.23 M |
| Dec 2019 | -$7.67 M | - | - |
FAQ
- What is Monte Rosa Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics annual EBITDA year-on-year change?
- What is Monte Rosa Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics quarterly EBITDA year-on-year change?
- What is Monte Rosa Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics TTM EBITDA year-on-year change?
What is Monte Rosa Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of GLUE is -$137.09 M
What is the all time high annual EBITDA for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$7.67 M
What is Monte Rosa Therapeutics annual EBITDA year-on-year change?
Over the past year, GLUE annual earnings before interest, taxes, depreciation & amortization has changed by -$28.45 M (-26.19%)
What is Monte Rosa Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of GLUE is -$24.42 M
What is the all time high quarterly EBITDA for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$4.23 M
What is Monte Rosa Therapeutics quarterly EBITDA year-on-year change?
Over the past year, GLUE quarterly earnings before interest, taxes, depreciation & amortization has changed by +$10.71 M (+30.48%)
What is Monte Rosa Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of GLUE is -$121.07 M
What is the all time high TTM EBITDA for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$4.23 M
What is Monte Rosa Therapeutics TTM EBITDA year-on-year change?
Over the past year, GLUE TTM earnings before interest, taxes, depreciation & amortization has changed by +$14.42 M (+10.64%)